Carregant...
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia
ABL tyrosine kinase inhibitors (TKIs) dramatically improves chronic myeloid leukemia (CML) prognosis and most CML patients are now able to lead lives that are equivalent to those of healthy individuals. However, high cost to CML patients of long-term treatment and adverse effects (AEs) remain proble...
Guardat en:
| Publicat a: | Stem Cell Investig |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4981735/ https://ncbi.nlm.nih.gov/pubmed/27583255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2016.07.08 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|